tion the original report should be consulted.
Cholera.?Two enquiries were conducted under this head during the year : (1) At the Calcutta School of Tropical Medicine on the treatment of cholera with sulpha drugs.?In a series of cholera cases treated with sulphaguanidine the evidence was in favour of sulphaguanidine. As these trials were not extensive, no definite conclusion could be arrived at. A small series of cholera patients under field conditions were treated with this drug with encouraging results. A number of laboratory tests were performed which showed that sulphaguanidine has a destructive action on the causative organism of cholera.
(2) Evaluation of anti-cholera inoculations in Madras. ?The following is a summary of some of the data obtained and the conclusions drawn :
(i) In a population of about 3 millions exposed to the risk of contracting cholera there were 708,977 inoculated or protected persons, amongst these 1,128 cases of cholera occurred. In 2,119,568 uninoculated persons there were 34,336 cases of cholera. The incidence of cholera in these two groups was 1.57 and 16.20 per 1,000 respectively, viz, the incidence in the uninoculated was 1(5.3 times more than in the protected group.
Out of 2,350 villages under survey 627 villages had a second outbreak of cholera a month or more after the last case in the first outbreak. In these villages there were 541,808 uninoculated persons while the inoculated or protected persons numbered 281,484, the greater proportion of whom had been inoculated in the first outbreak. In the second outbreak 6,580 cases of cholera occurred in the uninoculated group and 241 in the inoculated group; the case incidence rates per 1,000 in the two groups being 12.14 and 0.86 respectively. The incidence in the uninoculated was 14.2 times more than in the inoculated or protected group.
The uninoculated persons run 10 to 14 times greater risk of contracting cholera than the inoculated persons in a community.
(ii) In the whole survey, there were 1,118 cases of cholera with 474 deaths in the inoculated group, and 50,053 cases with 27,576 deaths in the uninoculated group, the case fatality rates in the two groups being 42.4 
